
    
      Termination criteria

        1. Serum AST or ALT > 3 times ULN

        2. Total serum bilirubin > 1.5 times ULN

             -  no study termination of a patient with documented Gilberts disease for an isolated
                bilirubin elevation unless it exceeds 2.5x the upper limit of normal.

        3. Hematocrit > 55%

        4. Subject experiences any unacceptable or intolerable adverse effect.

        5. Subject is non-compliant with the study protocol.

        6. Subject needs to take any medication that would interfere with study measurements

        7. Subject develops prostate or breast cancer
    
  